Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States. Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A
Exscientia Announces Investment of up to $525M
Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities
$225 million Series D round closed with access up to an additional $300 million at Exscientia s discretion
Financing led by SoftBank Vision Fund 2
Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2
i led the Series D and was joined by previous round lead investors, Novo Holdings and funds managed by Blackrock. Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company s discretion.
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.